Ardelyx Stock Price, News & Analysis

Ardelyx, Inc. (Nasdaq: ARDX) has launched a new podcast called 'Gut Matters: Discoveries and Innovations' for the irritable bowel syndrome with constipation (IBS-C) patient community. The podcast is co-hosted by Johannah Ruddy, M.Ed., Ardelyx's director of patient advocacy, and Dr. Andrea Shin, a practicing gastroenterologist.

The monthly podcast will feature discussions with patients, caregivers, advocacy leaders, healthcare providers, and gastroenterology experts about the impact of IBS-C. It aims to provide education, hope, and valuable insights for those affected by the condition. The hosts hope to create a safe space where people with IBS-C can find fact-based information and hear relatable stories, empowering patients and their support networks.

The first episode is already available, and interested individuals can subscribe to the podcast on various platforms.

Ardelyx (Nasdaq: ARDX) has launched the Derek Forfang Patient Advocate Award to honor passionate supporters of chronic kidney disease (CKD) patients. The award, named after the late Derek Forfang, aims to recognize individuals who raise awareness of CKD challenges and advocate for the community.

Nominations are open until January 31, 2025, and can be submitted by anyone in the community. Recipients will receive a $1,000 honorarium and a $4,000 donation to a non-profit supporting the CKD community. Eligible nominees must demonstrate achievements in advocating for CKD patients, such as raising awareness, educating others, and advancing research.

The Derek Forfang Patient Advisory Council (DFPAC) will consider candidates for the award. Ardelyx emphasizes the importance of supporting and celebrating voices in the CKD community through this initiative.

Ardelyx (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative, first-in-class medicines for significant unmet medical needs, has announced its plans to report third quarter 2024 financial results on October 31, 2024. The company will host a conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update.

Interested parties can participate in the conference call by dialing (877) 346-6112 (domestic) or (848) 280-6350 (international) and asking to join the Ardelyx call. A live audio webcast will be available on the company's website under the Investors section at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call.

Ardelyx (Nasdaq: ARDX) announced that additional data supporting XPHOZAH® (tenapanor) will be presented at the American Society of Nephrology's (ASN) Kidney Week, October 24-27, 2024, in San Diego. XPHOZAH, the first and only phosphate absorption inhibitor (PAI), is FDA-approved to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy.

Two poster presentations will be featured:

• Sustained Phosphate Reduction Assessed by P AUC With Tenapanor Is Associated With Reduced Fibroblast Growth Factor 23 in Patients With CKD and Hyperphosphatemia on Dialysis
• Tenapanor Reduces Serum Phosphate With Similar Efficacy and Tolerability Profiles When Added to Various Phosphate Binders

Additionally, Ardelyx is sponsoring an Exhibitor Spotlight on October 25, 2024, discussing XPHOZAH's mechanism of action, efficacy, and safety data from Phase 3 clinical trials.

Ardelyx, Inc. (Nasdaq: ARDX) announced the publication of a review article titled 'Review of the Patient Burden and Therapeutic Landscape of Irritable Bowel Syndrome With Constipation in the United States' in Clinical and Experimental Gastroenterology. The article provides an overview of treatment options and disease management for irritable bowel syndrome with constipation (IBS-C) from a U.S. perspective.

Key points from the article include:

• The high disease burden of IBS-C, affecting economic, social, and mental health aspects
• The importance of the patient-healthcare provider relationship in diagnosis and treatment
• Recommendation for a positive diagnostic strategy based on clinical history, physical examination, and minimal laboratory tests
• Review of the treatment journey, from lifestyle interventions to FDA-approved therapies
• Mention of IBSRELA® (tenapanor) as one of the approved therapies, with data from T3MPO-1 and T3MPO-2 studies included

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative, first-in-class medicines, has announced its participation in the 2024 Cantor Global Healthcare Conference. Justin Renz, the company's Chief Financial and Operations Officer, will engage in a fireside chat on Thursday, September 19, 2024, at 9:10 A.M. Eastern Time in New York City.

Interested parties can access a live webcast of the panel presentation through the Events and Presentations page on the Ardelyx website. For those unable to attend, a replay of the fireside chat will be available on the company's website for 30 days following the event, providing an opportunity for investors and stakeholders to gain insights into Ardelyx's operations and future plans.

Ardelyx, Inc. (Nasdaq: ARDX) has appointed Eric Foster as Chief Commercial Officer. With over 23 years of commercial experience in biotech and pharmaceuticals, Foster will lead commercial strategies for Ardelyx's first-in-class medicines, IBSRELA® and XPHOZAH®. His extensive background includes leadership roles at Amgen, Horizon Therapeutics, GlaxoSmithKline, and Johnson & Johnson.

Mike Raab, CEO of Ardelyx, praised Foster's expertise and track record in developing businesses across multiple therapeutic areas. Foster expressed excitement about joining Ardelyx, highlighting the company's strong culture, commercial execution, and financial position. He aims to advance Ardelyx's commercial strategy and expand patient access to their innovative medicines.

Ardelyx reported strong Q2 2024 financial results, with significant revenue growth from its two key products. IBSRELA generated $35.4 million in net product sales, showing 25% quarter-over-quarter growth. XPHOZAH recorded $37.1 million in net product sales, up from $15.2 million in Q1. The company ended Q2 with approximately $186 million in cash and investments.

Total revenue for Q2 2024 was $73.2 million, compared to $22.3 million in Q2 2023. Net loss for Q2 2024 was $16.5 million, or $(0.07) per share. Ardelyx continues to expect full-year 2024 U.S. net product sales revenue for IBSRELA to be between $140.0 and $150.0 million.

The company is taking legal action against CMS to protect patient access to XPHOZAH, following concerns about potential access restrictions due to proposed policy changes.

Ardelyx, Inc. (Nasdaq: ARDX) has published plain language summaries of two clinical trials for XPHOZAH® (tenapanor) in Current Medical Research and Opinion. These summaries, from the NORMALIZE and OPTIMIZE studies, aim to help patients with chronic kidney disease on dialysis understand the safety and efficacy data of XPHOZAH. The FDA-approved drug is the first and only phosphate absorption inhibitor designed to reduce serum phosphorus in adult CKD patients on dialysis. It's used as an add-on therapy for patients with inadequate response to or intolerance of phosphate binders. XPHOZAH's unique mechanism blocks phosphate absorption at the primary pathway and is administered as a single tablet twice daily. The summaries provide accessible information about XPHOZAH's potential impact on lowering serum phosphorus levels, helping patients and caregivers make informed decisions about treatment options.